Neurocysticercosis

University of California San Francisco

National Institutes of Health Clinical Center, 9000 Rockville Pike

UT Southwestern Medical Center

University of Washington

People Presenting With Neurocysticercosis in North America

NACC 002: A Multicenter Prospective Natural History Study of Patients Presenting With Neurocysticercosis in North America

National Institute of Allergy and Infectious Diseases (NIAID)

albendazole, 15 mg/kg/day for those less than 50 kg in weight. For those more than 50 kg, 800 mg was administered. All got standard symptomatic therapy
placebo plus standard symptomatic therapy

Active drug or placebo dosed bid p o for 8days

albendazole

placebo

Vicente Corral Moscoso Hospital of Cuenca, Centro de Epilepsia, Facultad de Ciencias Médicinas de la Universidad de Cuenca IDIUC (Área 5), Av. 12 de Abril. Cdla.

Teodoro Maldonado Carbo Hospital, Av. 25 de Julio Vía Puerto Marítimo

Baca Ortiz Children's Hospital, Av. Colon s/n y 6 de Diciembre

Hospital Carlos Andrade Marin, Av. 10 de agosto y Bogotá

Hospital Eugenio Espejo, Servicio de Neurología, Av. Colombia s/n

A Pilot Study of Neurocysticercosis Treatment

W Allen Hauser, Professor of Neurology and Epidemiology, College of Physicians and Surgeons and Mailman School of Public Health

Columbia University

National Institute of Neurological Disorders and Stroke (NINDS)

Male and female subjects aged 3-75 years with likely or definite neurocysticercosis (NCC) diagnosis

Cysticercosis

Treatment of Patients With Cysticercosis With Praziquantel or Albendazole

Treatment of Cysticercosis Including Neurocysticercosis With Praziquantel, Albendazole and Other Novel Treatment Modalities

To study the clinical course of cysticercosis following therapy and diminish morbidity associated with treatment of cysticercosis including neurocysticercosis or the inflammation associated with therapy